{"article": [{"url": "https://www.marketwatch.com/story/pfizers-stock-surges-after-profit-and-revenue-beats-raised-guidance-2020-07-28", "published": 1595919980.0, "headline": "Pfizer's stock surges after profit and revenue beats, raised guidance", "body": "Shares of Pfizer Inc. PFE, -0.27% surged 3.4% in premarket trading Tuesday, after the drug maker reported profit and revenue that beat expectations and raised its full-year outlook, despite the challenges resulting from the COVID-19 pandemic. The results come after Pfizer and BioNTech SE BNTX, +1.23% said late Monday that a late-stage trial of its COVID-19 vaccine candidate has started. Pfizer reported net income that fell to $3.43 billion, or 61 cents a share, from $5.05 billion, or 89 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share fell to 78 cents form 80 cents but beat the FactSet consensus of 67 cents. Revenue declined 11% to $11.80 billion but was above the FactSet consensus of $11.58 billion. Biopharma revenue rose 4% to $9.80 billion while Upjohn revenue dropped 32% to $2.01 billion. For 2020, the company raised its guidance ranges for adjusted EPS to $2.85 to $2.95 from $2.82 to $2.92 and for revenue to $48.6 billion to $50.6 billion from $48.5 billion to $50.5 billion. The stock has slipped 4.2% year to date through Monday, while the Dow Jones Industrial Average DJIA, +0.56% has declined 6.9%."}]}